Ingrid Goldberg | Vice President-Investor Relations, bluebird bio, Inc. |
Nick Leschly | Chief Bluebird & Director, bluebird bio, Inc. |
David M. Davidson | Chief Medical Officer, bluebird bio, Inc. |
William Denise Baird | Chief Financial Officer, bluebird bio, Inc. |
Joanne M. Smith-Farrell | Chief Business Officer, bluebird bio, Inc. |
Alison C. Finger | Chief Commercial Officer, bluebird bio, Inc. |
Cory Kasimov | Analyst, JPMorgan Securities LLC |
Salveen Richter | Analyst, Goldman Sachs & Co. LLC |
Mani Foroohar | Analyst, SVB Leerink LLC |
Yaron Werber | Analyst, Cowen & Co. LLC |
Biren Amin | Equity Analyst, Jefferies LLC |
Dane Leone | Analyst, Raymond James & Associates, Inc. |
Mark Breidenbach | Executive Director & Senior Analyst, Oppenheimer & Co., Inc. |
Vincent Chen | Analyst, Sanford C. Bernstein & Co. LLC |
Matthew Luchini | Analyst, BMO Capital Markets Corp. |
Jason M. Gerberry | Analyst, BofA Securities, Inc. |
Michael Schmidt | Analyst, Guggenheim Securities LLC |
Alexander D. Duncan | Analyst, Piper Sandler & Co. |
Gena Wang | Analyst, Barclays Capital, Inc. |
Benjamin J. Burnett | Analyst, Stifel, Nicolaus & Co., Inc. |
Josh Schimmer | Analyst, Evercore ISI |
Raju Prasad | Analyst, William Blair & Co. LLC |
Ladies and gentlemen, thank you for standing by, and welcome to the bluebird bio First Quarter 2020 Earnings Conference Call. At this time, all participants lines are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the conference over to Ingrid Goldberg.